Article in Neural regeneration research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Shaomin LiAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9451-2151
Jianlin WangDepartment of Neurology and the F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
Qianqin GuoAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Yunxin BaiAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Wen LiuAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Kevin J HodgettsLaboratory for Drug Discovery in Neurodegeneration, Brigham & Women's Hospital and Harvard Medical School, Cambridge, MA, USA.
Paul A RosenbergDepartment of Neurology and the F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
Dennis J SelkoeAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Funding
TRANSGENICS AND PRESENILIN FUNCTIONP01AG015379 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BEREZOVSKA, OKSANA · 1998 to 2023
$51.3M
SYNAPTIC MECHANISMS IN HIPPOCAMPAL EPILEPTOGENESISP30HD018655 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI WOOLF, CLIFFORD J · 1985 to 2015
$26.2M
Role of Astrocyte EAAT2/GLT1 Failure in Alzheimer's Disease PathogenesisR01AG075338 · NIA · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI Annalisa Scimemi · 2022 to 2026
$3.8M
An interneuronal signaling network governs the fate of retinal ganglion cells after optic nerve injuryR01EY027881 · NEI · BOSTON CHILDREN'S HOSPITAL · PI ROSENBERG, PAUL ALLEN · 2018 to 2022
$3.5M
Mechanisms underlying glutamate dyshomeostasis in Alzheimer's diseaseR03AG070766 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI LI, SHAOMIN · 2022 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Impairment of hippocampal long-term potentiation by soluble amyloid-β oligomers is mediated by glutamate transporter 1 expressed in neurons. · full record | OpenQuestion